Yang Cai-Qin, Wang Jing, Zhang Zhen-Wei
School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Guang Pu Xue Yu Guang Pu Fen Xi. 2011 Sep;31(9):2476-9.
Pharmaceutical co-crystals can improve the chemical and physical properties of active pharmaceutical ingredient (API), which is new idea and expected to provide new stable structures. Pharmaceutical co-crystals have the potential to be much more useful in pharmaceutical products than salts, solvates or hydrates, polymorphs and stoichiometric solvates (pseudo-polymorphs). In our study, dipfluzine hydrochloride-benzoic acid co-crystal was synthesized by solid co-grinding. The samples were subjected to IR, DSC, XRD, Raman and THz spectral analysis. The results indicated that dipfluzine hydrochloride-benzoic acid complex was new phase compared with the single API and CCF. THz-TDS characterization indicated that hydrogen bond formed between API and CCF, which confirmed the formation of co-crystal.
药物共晶体可以改善活性药物成分（API）的化学和物理性质，这是一个新的理念，有望提供新的稳定结构。药物共晶体在药品中的应用潜力可能比盐、溶剂化物或水合物、多晶型物和化学计量溶剂化物（假多晶型物）更大。在我们的研究中，通过固体共研磨合成了盐酸地氟嗪-苯甲酸共晶体。对样品进行了红外光谱（IR）、差示扫描量热法（DSC）、X射线衍射（XRD）、拉曼光谱和太赫兹光谱分析。结果表明，与单一API和CCF相比，盐酸地氟嗪-苯甲酸复合物是新的物相。太赫兹时域光谱（THz-TDS）表征表明API和CCF之间形成了氢键，这证实了共晶体的形成。
